Cargando…

Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network

Mechanisms-of-resistance to decitabine and 5-azacytidine, mainstay treatments for myeloid malignancies, require investigation and countermeasures. Both are nucleoside analog pro-drugs processed by pyrimidine metabolism into a deoxynucleotide analog that depletes the key epigenetic regulator DNA meth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Xiaorong, Tohme, Rita, Tomlinson, Benjamin, Sakre, Nneha, Hasipek, Metis, Durkin, Lisa, Schuerger, Caroline, Grabowski, Dale, Zidan, Asmaa M., Radivoyevitch, Tomas, Hong, Changjin, Carraway, Hetty, Hamilton, Betty, Sobecks, Ronald, Patel, Bhumika, Jha, Babal K., Hsi, Eric D., Maciejewski, Jaroslaw, Saunthararajah, Yogen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867667/ https://www.ncbi.nlm.nih.gov/pubmed/32770088 http://dx.doi.org/10.1038/s41375-020-1003-x

Ejemplares similares

Extended experience with a non‐cytotoxic DNMT1‐targeting regimen of decitabine to treat myeloid malignancies
por: Awada, Hassan, et al.
Publicado: (2019)

PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation
por: Gu, Xiaorong, et al.
Publicado: (2021)

Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia
por: Guan, Yihong, et al.
Publicado: (2022)

A non‐cytotoxic regimen of decitabine to treat refractory T‐cell large granular lymphocytic leukemia
por: Zawit, Misam, et al.
Publicado: (2021)

Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia
por: Guan, Yihong, et al.
Publicado: (2020)

Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen
por: Saleh, Mostafa F. M., et al.
Publicado: (2017)

Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma
por: Hasipek, Metis, et al.
Publicado: (2021)

High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects
por: Ebrahem, Quteba, et al.
Publicado: (2012)

Decitabine Suspends Human CD34(+) Cell Differentiation and Proliferation during Lentiviral Transduction
por: Uchida, Naoya, et al.
Publicado: (2014)

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors
por: Negrotto, Soledad, et al.
Publicado: (2011)

Multiple Myeloma Therapy: Emerging Trends and Challenges
por: Dima, Danai, et al.
Publicado: (2022)

Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion
por: Chilakala, Sujatha, et al.
Publicado: (2019)

Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF
por: Ibanez, Vinzon, et al.
Publicado: (2023)

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line
por: Aumer, Tina, et al.
Publicado: (2022)

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
por: Imanishi, Satoshi, et al.
Publicado: (2017)

Azacytidine and Decitabine Induce Gene-Specific and Non-Random DNA Demethylation in Human Cancer Cell Lines
por: Hagemann, Sabine, et al.
Publicado: (2011)

A Perspective on the Comparative Antileukemic Activity of 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)
por: Momparler, Richard L.
Publicado: (2012)

S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis)
por: Lavelle, Donald, et al.
Publicado: (2010)

Novel pharmacologic approach to enhance the epigenetic and immune priming effect of decitabine in patients with advanced non-small cell lung cancer
por: Velcheti, Vamsidhar, et al.
Publicado: (2015)

Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: identification of functional disparities between azacytidine and decitabine
por: Hsieh, Yao-Yu, et al.
Publicado: (2016)

P524: PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
por: Fedorov, Kateryna, et al.
Publicado: (2023)

Targeting sickle cell disease root-cause pathophysiology with small molecules
por: Saunthararajah, Yogen
Publicado: (2019)

Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation
por: Saunthararajah, Yogen
Publicado: (2020)

Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study
por: Molokie, Robert, et al.
Publicado: (2017)

dNTP Supply Gene Expression Patterns after P53 Loss
por: Radivoyevitch, Tomas, et al.
Publicado: (2012)

Correction: Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: identification of functional disparities between azacytidine and decitabine
por: Hsieh, Yao-Yu, et al.
Publicado: (2018)

Molecular features of early onset adult myelodysplastic syndrome
por: Hirsch, Cassandra M., et al.
Publicado: (2017)

Post‐transcriptional regulation of PIAS3 expression by miR‐18a in malignant mesothelioma
por: He, Tian, et al.
Publicado: (2018)

RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR
por: Sakre, Nneha, et al.
Publicado: (2016)

Distinctive and common features of moderate aplastic anaemia
por: Patel, Bhumika J., et al.
Publicado: (2020)

5613127 PHARMACOKINETICS AND PHARMACODYNAMICS OF AN INNOVATIVE ORAL FORMULATION OF DECITABINE AND TETRAHYDROURIDINE IN HEALTHY PEOPLE
por: Saunthararajah, Y., et al.
Publicado: (2023)

Vitamin C promotes decitabine or azacytidine induced DNA hydroxymethylation and subsequent reactivation of the epigenetically silenced tumour suppressor CDKN1A in colon cancer cells
por: Gerecke, Christian, et al.
Publicado: (2018)

Development of an Oral Form of Azacytidine: 2′3′5′Triacetyl-5-Azacytidine
por: Ziemba, Amy, et al.
Publicado: (2011)

5-aza-2′,2′-Difluroro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer
por: Daifuku, Richard, et al.
Publicado: (2017)

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1
por: Saygin, Caner, et al.
Publicado: (2018)

Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells
por: Enane, Francis O., et al.
Publicado: (2018)

Azacytidine Treatment for VEXAS Syndrome
por: Raaijmakers, Marc H. G. P., et al.
Publicado: (2021)

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2022)

New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists
por: Carraway, Hetty, et al.
Publicado: (2004)

Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes
por: Raj, Kavita, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_h2ue8rk38ique6kvi3kq1rv0tk